FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to a pharmaceutical composition for treating diseases including cell proliferation, using it, and a kit containing the combined administration of a compound
wherein groups L, R1, R2, R3, R4 and R5 have the values presented in the patent claim and description, optionally in the form of tautomers, racemates, enanthiomers, diastereomers, and mixtures thereof, and optionally in the form of its pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphic forms, physiologically functional derivatives or prodrugs, and an effective amount of an active compound
EFFECT: preparing the pharmaceutical composition for treating diseases including cell proliferation.
5 cl, 8 dwg, 2 tbl, 24 ex
Title | Year | Author | Number |
---|---|---|---|
NEW CHEMICAL COMPOUNDS (VERSIONS) AND USING THEM FOR TREATING ONCOLOGICAL DISEASES | 2013 |
|
RU2550346C2 |
NEW N-SULFAMOYLPIPERIDINEAMIDS DESIGNED FOR PREVENTION OR TREATMENT OF FATTY DEGENERATION AND CONGENEROUS PATHOLOGICAL CONDITIONS | 2006 |
|
RU2442773C2 |
TRICYCLIC ANTITUMOR COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATMENT BASED ON THEREOF | 2001 |
|
RU2293734C9 |
PYRIMIDINE COMPOUNDS OF ANTIPROLIFERATIVE ACTION (II) | 2003 |
|
RU2326882C2 |
MULTIKINASE INHIBITOR COMPOUND AND ITS CRYSTALLINE FORM AND USE | 2017 |
|
RU2723985C1 |
PYRIMIDINE INDOLE COMPOUNDS | 2010 |
|
RU2552999C2 |
COMPOUNDS, COMPOSITIONS AND METHODS SUITABLE FOR CHOLESTEROL MOBILISATION | 2011 |
|
RU2576402C2 |
CRYSTAL FORM OF PHOSPHODIESTERASE INHIBITOR, METHOD OF ITS PREPARATION AND USE | 2020 |
|
RU2814498C2 |
PYRIDILAMINE FUMARATE AND ITS CRYSTALS | 2015 |
|
RU2684278C1 |
NOVEL CHEMICAL COMPOUNDS - 2,4-DIAMINO-1,3,5-TRIAZINE DERIVATIVES FOR PREVENTING AND TREATING HUMAN AND ANIMAL DISEASES | 2012 |
|
RU2509770C2 |
Authors
Dates
2014-06-27—Published
2005-08-09—Filed